press releases

Press Release TEL AVIV, Israel – June 4, 2024 – Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a potential new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced that the first patient has been enrolled in the ASTRO study – a Phase 3 clinical trial assessing the efficacy and safety of […]

Press Release Azura to present 10 abstracts at the American Society of Cataract and Refractive Surgery (ASCRS) and the Association for Research in Vision and Ophthalmology (ARVO), showcasing a breadth of data supporting the potential for a new therapeutic class to treat underserved ophthalmic conditions New and updated data show investigational AZR-MD-001 demonstrates durability of

Press Release Study met its primary endpoint and showed significant and clinically meaningful improvements in multiple symptoms of Contact Lens Discomfort and signs of concomitant Meibomian Gland Dysfunction Patients in the AZR-MD-001 arm gained at least three hours of comfortable contact lens wear time daily and had improvements in both tear break up time and

Press Release Robust safety and efficacy data supports advancing AZR-MD-001 into Phase 3 clinical trials TEL AVIV, Israel – April 20, 2023 – Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced multiple presentations featuring positive efficacy and safety data from a Phase

Press Release TEL AVIV, Israel & MELBOURNE, Australia, January 17, 2023 – Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced that its executive team will hold 1×1 investor meetings during the Private Company Track of the 2023 SVB Securities Global Biopharma Conference being

Press Release TEL AVIV, Israel & MELBOURNE, Australia, December 9, 2022 – Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced that positive 3-month efficacy and safety results from its Phase 2b study of AZR-MD-001 0.5% in Meibomian Gland Dysfunction (MGD), were presented for

Press Release TEL AVIV, Israel & MELBOURNE, Australia, November 21, 2022 – Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced that members of management will present at BTIG’s Ophthalmology Day 2022, being held on November 29, and at the Piper Sandler 34th

Press Release — AZR-MD-001 0.5% meets co-primary efficacy endpoints, making it the first investigational drug to show significant improvements in both signs and symptoms of Meibomian Gland Dysfunction — — Restoration of gland function shown to improve downstream response measures of ocular conditions associated with Meibomian Gland Dysfunction — — Rapidly advancing AZR-MD-001 to Phase

Press Release — Supports continued advancement of first-in-class Ophthalmic Keratolytics for ocular surface diseases — TEL AVIV, Israel & MELBOURNE, Australia, October 19, 2022 – Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced the company’s U.S. 11,459,351 patent (the ‘351 patent) was

Press Release   — Receives IND clearance for Phase 2b program in U.S.–— Topline data from ongoing Phase 2b clinical trial to be reported in Q4 2022 —   TEL AVIV, Israel & MELBOURNE, Australia, September 28, 2022 – Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for